FDA accepts Regeneron's sBLA for Eylea HD in RVO with priority review; QUASAR data supports monthly dosing, target action date set for August 2025.

Qure's AMT-130 shows 80% Huntington's Disease progression slowing. Click to read more on QURE's financially strong, advancing ...

Find Global Pharmaceuticals stock video, 4K footage, and other HD footage from iStock. Get higher quality Global Pharmaceuticals content, for less—All of our 4K video clips are the same price as HD.

Image source: Getty Images ... and remaining financially free. Here's how to get started the right way. If you're looking for maximum growth in your stock investments, you'll also want to look ...

Find Pharmaceutical Manufacturing Illustration stock video, 4K footage, and other HD footage from iStock. Get higher quality Pharmaceutical Manufacturing Illustration content, for less—All of our 4K ...

Especially since videos aren’t watermarked and support full HD exports ... Still, the free version houses a nice selection of stock images, music samples, and graphics to help your movies ...

She reiterated her buy recommendation on Vertex stock, and kept her $583-per-share ... part of a broader dive into the current state of pharmaceutical stocks by investment bank Cantor Fitzgerald.

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) were skyrocketing around 20% higher as of 11 a.m. ET on Friday. The big gain for the biotech stock came after the U.S. Food and Drug ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals ... Image source: Getty Images. With cystic fibrosis therapies ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about ...